Rituximab, a CD20-specific monoclonal antibody that depletes B cells, has shown promising results in patients with relapsing-remitting multiple sclerosis. Studies of experimental autoimmune ...
The following is a summary of “Tumor and Blood B Cell Abundance Outperforms Established Immune Checkpoint Blockade Response ...
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the ...
It is likely that B-cell-derived regulatory IL-10 has evolved to serve distinct immune functions, and that these functions are in turn carefully regulated in a cell-subset- and context-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback